| Document |
Document Title |
|
WO/2013/104346A1 |
The invention provides new lipopolyamines of spermine type of the general formula I, wherein X is C-N bond or aminopolyethyleneglycolcarboxamide linker or o-hydroxy- alkylcarboxamide linker or ω-hydroxyalkylcarboxamidopolyethyleneglycol...
|
|
WO/2013/106238A1 |
The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof. Also, the present invention provides a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically accepta...
|
|
WO/2013/054273A9 |
The present invention provides a process for the preparation of agomelatine and its intermediate compounds. The invention also provides intermediate compounds of agomelatine represented by Formula IV, Formula V and Formula VIII.
|
|
WO/2013/063679A9 |
Use of Neu1 sialidase inhibitors for the treatment of cancer as a monotherapy or in combination with known chemotherapeutics. Preferably, Neu1 sialidase inhibitors are oseltamivir phosphate or 2-deoxy-2,3-dehydro-N-acetylneuraminic acid ...
|
|
WO/2013/102626A1 |
The invention relates to 3-[4-(phenylaminooxalylamino)phenyl]hex-4-ynoic acids, and to physiologically compatible salts thereof. The invention relates to compounds of the formula (I) in which R1, R2, R3 and R4 are each defined as specifi...
|
|
WO/2013/094108A1 |
Provided is a method for producing an optically active ceramide by an N-acylation (amidation) reaction of an optically active aminodiol, wherein a crude ceramide produced therein is purified by an industrially advantageous process. Namel...
|
|
WO/2013/093458A2 |
This invention relates to derivatives of antiviral drug compounds. It also relates to pharmaceutical formulations of derivatives of antiviral drug compounds. It also relates to uses of the derivatives in treating viral infections and in ...
|
|
WO/2013/092076A1 |
The invention relates to a process for preparing N-alkyl(meth)acrylamides by reaction of (meth)acrylic anhydride with corresponding alkylamines.
|
|
WO/2013/093320A1 |
The invention relates to the use of 1-aryl-2-aryloxyethane compounds with formula I, wherein n and m are equal to 0 or 1, provided that n+m=1, R1 and R2 particularly representing hydrogen atoms, R3 and R4 particularly representing hydrog...
|
|
WO/2013/090460A1 |
A composition for increasing the bioavailability of Acetaminophen in humans and animals, comprising Acetaminophen, a first water soluble surfactant having a cloud point greater than about 37° C, a second water soluble surfactant having ...
|
|
WO/2013/084237A1 |
This invention relates to deuterated tetramethyl dioic acids, compositions comprising them and uses thereof in the treatment of Metabolic Syndrome and any diseases, disorders or symptoms associated therewith.
|
|
WO/2013/084238A1 |
The present invention relates to isolated stereoisomeric forms of the compound (S)2-N(3- 0-(propan 2-ol)-l-propyl-4-hydroxybenzene)-3-phenylpropylamide. Specifically, the present invention relates to the use of (S)2-N(3-0-((S)propan 2-ol...
|
|
WO/2013/079421A1 |
The invention relates to a method for converting carbon dioxide or bicarbonates into formic acid derivatives, i.e. formate salts, formate esters, and formamides, using molecular hydrogen and a catalytic system comprising a cobalt complex...
|
|
WO/2013/080095A1 |
The present invention provides a process for the preparation of agomelatine and its intermediate compounds. The invention also provides an intermediate compound of agomelatine represented by Formula (V).
|
|
WO/2013/079578A1 |
The present invention provides a simplified method for the preparation of F-labelled compounds that is particularly suitable for automation. The method of the invention is specifically applicable where the 18F-labelled compound is prepar...
|
|
WO/2013/079687A1 |
Disclosed herein are α-galactosylceramide (α-GalCer) analogs and compositions thereof, methods of activating invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said a...
|
|
WO/2013/082302A1 |
The present invention provides an Agomelatine-urea complex, and a specific crystalline form thereof.
|
|
WO/2013/075630A1 |
The present invention provides a nano particle of a nucleic acid. The nano particle of a nucleic acid is composed of a plurality of single chain nucleic acid units, the single chain nucleic acid units comprising three-head single chain n...
|
|
WO/2013/076630A1 |
A novel process for racemization of (S)-3-carbamoylmethyl-5-methyl-hexanoic acid to 3-carbamoylmethyl-5-methyl-hexanoic acid racemate has been developed.
|
|
WO/2013/070118A1 |
This invention relates to novel substituted 4,5-diamino-3-alkyloxy- cyclohex-1-ene carboxylic acids, esters thereof or pharmaceutically acceptable salts and/or hydrates, to novel antiviral medicines - inhibitors of the activity of neuram...
|
|
WO/2013/067579A1 |
Disclosed are methods and compositions for modulating adiposity-related conditions, which utilize inhibitors of phospholipase A2, and more particularly phospholipase A2 Group IIa (PLA2G2A). Representative adiposity-related conditions inc...
|
|
WO/2013/065867A1 |
The present invention relates to a novel method for producing an optically active β-hydroxy-α-aminocarboxylic acid ester, the method comprising performing an asymmetric reduction reaction of a β-keto-α-aminocarboxylic acid ester by u...
|
|
WO/2013/064031A1 |
Disclosed are an N-benzylaniline derivative and uses thereof. The derivative is a compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound has an action of protecting against cerebral ischemia/reperfu...
|
|
WO/2013/067163A1 |
In one aspect, the invention relates to compounds having the formula: (I) where R1-R6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. I...
|
|
WO/2013/060011A1 |
Disclosed is a direct acid catalyzed intermolecular electrocyclic rearrangement process for the preparation of linear and cyclic homoallylic ester and amides.
|
|
WO/2013/063289A1 |
A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I, for the prevention or treatment of pain and pain related disorders is provided. The pharmaceutical compositions are useful in a method...
|
|
WO/2013/060964A1 |
The invention relates to a compound of formula (I): R'-O-A-O-R'', in which R' and R" are a hydrogen atom or a monovalent radical of formula (IIa), or a monovalent radical of formula (IIb), it being understood that at least one of the rad...
|
|
WO/2013/060818A1 |
Disclosed is a direct acid catalyzed intermolecular electrocyclic rearrangement process for the preparation of linear and cyclic homoallylic ester and amides.
|
|
WO/2013/062028A1 |
Provided are a novel compound having an antiviral effect, particularly HIV replication-inhibiting activity, and a medical drug, particularly an anti-HIV drug, containing the same. The compound is represented by Formula (I) (where the bro...
|
|
WO/2013/060097A1 |
The present invention provides compounds having the structure represented by general formula I, pharmaceutically acceptable salts thereof, preparation methods therefor and a use thereof in the preparation of a medicine for the treatment ...
|
|
WO/2013/059215A1 |
Disclosed herein are substituted biaryl alkyl amide compounds, methods of synthesizing substituted biaryl alkyl amide compounds and methods of treating diseases and/or conditions with substituted biaryl alkyl amide compounds.
|
|
WO/2013/059203A1 |
This invention provides a compound having the structure (I) wherein α, β, A, B, and R1-R4 are defined herein. This invention also provides pharmaceutical compositions comprising the above compounds, a method of accelerating the healing...
|
|
WO/2013/057619A1 |
The present invention provides novel phenicol derivatives, their use for the treatment of infections in mammals, pharmaceutical compositions containing these novel compounds, and methods for the preparation of these compounds.
|
|
WO/2013/059582A2 |
The disclosure relates to small molecules and methods, compositions, and kits comprising these small molecules. In still another embodiment, the disclosure relates to small molecules that inhibit HDAC activity. In yet another embodiment,...
|
|
WO/2013/059788A1 |
A process for preparing a compound of Formula I is disclosed, comprising the steps: wherein: R1 is halo; R2 is halo; R3 is (C1-C6)alkyl or (C1-C6)alkyl optionally substituted with heterocycloalkyl; R4 is (C1-C6)alkyl; and Q is CH orN; co...
|
|
WO/2013/055687A2 |
The subject invention provides R (+) -N-formyl-propargyl- aminoindan and a composition containing N-propargyl-1 (R) -aminoindan or a pharmaceutically acceptable salt thereof, and a compound of R (+) -N-formyl-propargyl-aminoindan.
|
|
WO/2013/055198A1 |
The invention relates to a water-based vinyl-acrylic paint comprising phase-change materials suitable for encapsulating capsicum or capsaicin oleoresin derived directly from the placenta of the chili. In addition, in one of the embodimen...
|
|
WO/2013/041895A1 |
The invention relates to novel compounds of general formula (I), and their preparation, pharmaceutical preparations containing compounds of general formula (I), and the use of these compounds in therapeutic procedures. The invention also...
|
|
WO/2013/038985A1 |
Provided is a method for selectively N-acylating an amino triol to produce an N-acylated amino triol efficiently and by a technique that is industrially advantageous. A method for producing an N-acylamino triol represented by formula (1)...
|
|
WO/2013/039819A2 |
Carbon nanostmctures may be protected and functionalized using a layer-by-layer method whereby functional groups on the carbon nanostmcture surface may be further derivatized to incorporate additional functional moieties. Exemplary moiet...
|
|
WO/2013/039858A2 |
Carbon nanostmctures may be protected and functionalized using a layer-by-layer method whereby functional groups on the carbon nanostmcture surface may be further derivatized to incorporate additional functional moieties. Carbon nanostmc...
|
|
WO/2013/034457A1 |
The invention provides novel lipophilic dopamine derivatives with improved stability and physiological half-life. The compounds may be used for organ and tissue preservation during storage and transport, or in the pre-treatment of organ ...
|
|
WO/2013/035827A1 |
The purpose of the present invention is to provide: a novel compound which is represented by formula (I') and has ACC2 inhibitory activity; and a medicinal composition which contains the compound. (In the formula, R1 represents a substit...
|
|
WO/2013/029648A1 |
A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: - R' is H or F or trifluoromethyl; - R'' is OH or O-alkyl; - R''' is H or F or trifluoromethyl or phenyl or pyridyl; - R'''' is methylene or acy...
|
|
WO/2013/030358A1 |
The invention relates to 4-aminonaphthalene-2-carboxylic acids and 1-amino- isoquinoline-3-carboxylic acids as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compou...
|
|
WO/2013/033602A2 |
The invention relates to fatty acid amides; compositions comprising an effective amount of a fatty acid amide; and methods for treating or preventing cancer, a metabolic disease or a neurodegenerative disease comprising the administratio...
|
|
WO/2013/032973A1 |
An aromatic amide compound having the following general formula (I) is provided: wherein, X1 and X2 are independently C(O)HN or NHC(O); G1, G2 and G3 are independently hydrogen, C(O)HN-phenyl, or NHC(O)-phenyl, wherein at least one of G1...
|
|
WO/2013/028543A1 |
The disclosure relates to BAX activators and therapeutic uses relates thereto. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, comprising administering a therapeutically ef...
|
|
WO/2013/026765A1 |
The present invention relates to novel compounds of formulae (I) and (II) which are useful in the prevention, treatment and diagnosis, in vivo diagnosis of diseases or disorders related to S1P receptors, in particular, in diseases which ...
|
|
WO/2013/028570A2 |
The present invention provides methods of making and using peripherally restricted inhibitors of fatty acid amide hydrolase (FAAH). The present invention provides compounds and compositions that suppress FAAH activity and increases anand...
|
